Novigenix supports the healthcare community in saving lives through innovative screening of cancer
Novigenix is an innovative Swiss molecular diagnostics company specializing in the development of screening and diagnostic tools for the early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early diagnosis and intervention.
Novigenix’s technology is based on a new generation of predictive gene expression profiles of circulating blood cells in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures provide new and accurate solutions for the early diagnosis of cancer.
Sahar Hosseinian, PhD
Biostatistician and Clinical Program Manager
Sylvain Monnier-Benoit, PhD
Product Development Program Manager
Laura Ciarloni, PhD
Clinical Development Manager
Philippe Monnier-Benoit, PhD
Senior Accountant and Office Manager
Claire Marie Gigon, MIBS
Director of Clinical Communication
Prof. Curzio Rüegg, MD
Director of Translational Medicine
Brian B Hashemi, PhD MBA
Luc André, LL.M
Director of Finance
Prof. Gian Dorta, MD
Department of Internal Medicine, Section Gastroenterology and Hepatology, Academic Medical Center, Lausanne (CHUV), Switzerland
Dr. Cristina Nichita, MD
Specialist in Gastroenterology, Department of Internal Medicine, Section Gastroenterology and Hepatology, Academic Medical Center, Lausanne (CHUV), Switzerland
Dr. Philippe Maerten, MD PhD
Specialist in Gastroenterology, Lausanne, Switzerland
Colorectal cancer is the second leading cause of cancer mortality in men and women in Europe1. The number of cases is expected to increase over the next two decades as a result of the aging population. Fortunately, colorectal cancer is highly curable if diagnosed early, and may be prevented through removal of adenomatous polyps.
Most colorectal cancers develop slowly over several years. They often start as benign precursor lesions called adenomatous polyps, which develop over time into colorectal cancer. Localized tumors confined to the wall of the colon are often curable with surgery. Over 90% of patients diagnosed at this early stage can survive the disease. However, if left untreated, the cancer will spread, reducing the survival rate to 70%. Once the cancer metastasizes the survival rate is further reduced to 10%2.
The European Commission3 and the Ligue Suisse Contre le Cancer4 recommend regular screening beginning at the age of 50 for average-risk populations as an essential measure for early diagnosis and intervention of colorectal cancer. Recommended tools for colorectal cancer screening in Europe currently include colonoscopy and fecal occult blood tests. Unfortunately, however, due to lack of convenience and fear of invasive procedures, screening program compliance is alarmingly low, resulting in an unnecessary and preventable high incidence and mortality rate of colorectal cancer.
Novigenix is committed to supporting patients and the healthcare community at large by providing a novel and convenient blood-based screening test to dramatically increase compliance to colorectal cancer screening. Each individual should contact their physician to determine which screening method is most suitable for their specific situation.
1) World Health Organization, International Agency for Research on Cancer, GLOBOCAN2012: Estimated Cancer Incidence, Mortality, and Prevelance Worldwide in 2012
2) Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Fatima A. Haggar et al. Clin Colon Surg. Nov 2009 22(4): 191-197
3) European guidelines for quality assurance in colorectal cancer screening and diagnosis
4) Ligue Suisse Contre Le Cancer
Colox® is a new non-invasive colorectal cancer screening blood test that is currently available through local medical laboratories in Switzerland. Colox® has proven to have significant benefits:
- It accurately and reliably detects both adenomatous polyps and early stages of colorectal cancer,
- It is a convenient blood test with no need for bowel or stool preparation,
- It can be ordered by the physician as part of a routine medical check-up,
Colox® has been validated through a multicenter clinical study in Switzerland detecting 78% of colorectal cancer patients, and more than half of patients with adenomatous polyps. Less than 1 out of 10 people without colorectal cancer or adenomatous polyps tested positive5. Individuals testing positive with Colox® have a high probability of having adenomatous polyps or colorectal cancer and should be referred for colonoscopy for further evaluation and final diagnosis. Individuals testing negative with Colox® should continue participating in a screening program at intervals recommended by their physician.
5) N. Imaizumi, S. Hosseinian, S. Monnier-Benoit, L. Ciarloni, A.Bujard, C. Ruegg, C. Nichita, G. Dorta. Development and validation of a blood test based on 29-gene expression for early detection of colorectal cancer; In preparation
How does Colox® work?
Colox® is based on the analysis of peripheral blood mononuclear cells (PBMCs) isolated from a routine blood sample. PBMCs are responsive to growing adenomatous polyps and colorectal carcinomas as part of the “host-response”6.
Colox® measures the gene expression profile of 29 biomarkers by real-time PCR in PBMCs. Gene expression data are interpreted by Novigenix’s proprietary algorithm which generates the Colox® test result. This algorithm is based on classifier combinations derived from state-of-the art mathematical analytical methods that underpin the reliability of the test7.
Colox® is available as a laboratory-developed test and is highly adaptable to standard medical laboratory workflows. Colox® is also available as a CE-registered kit (CH-201403-0018).
6) C. Nichita, L. Ciarloni, S. Monnier-Benoit, S. Hosseinian, G. Dorta, C. Ruegg. A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer; Aliment Pharmacol Ther. 2014 Mar; 39(5):507-17
7) L. Ciarloni, S. Hosseinian, S. Monnier-Benoit, N. Imaizumi, G. Dorta, C. Ruegg. Discovery of a 29-Gene Panel in Peripheral Blood Mononuclear Cells for the Detection of Colorectal Cancer and Adenomas Using High Throughput Real-Time PCR; PLoS ONE 10(4): e0123904
How can I be tested with Colox®?
Please contact your physician to see if Colox® is suitable for you. Colox® is currently available through the following local medical laboratories in Switzerland:
Ch. des Perrières 2
Tel. 022 716 21 10
Rue de la Vigie 5
Tel. 021 321 40 00
Av. De Belmont 25
Tel. 021 966 65 30
Rue de l’Hôpital 20
Tel. 032 722 16 80
Rue Saint Jean 11
Tel. 022 716 21 32
Rue des Collines 13
Tel. 027 327 52 00
Bvd Paderewski 3
Tel. 021 923 42 06
Rue Vautier 2
Tel. 022 716 21 11
Av. Jules-Crosnier 8
Tel. 022 702 98 98
Cité Universitaire Bât. D
Tel. 022 716 21 70
Rue de Lausanne 20
Tel 022 716 21 13
Av. Frontenex 1, 6
Tel. 022 707 91 40
Unilabs GE-La Colline
Av. de Beau-Séjour 6
Tel. 022 702 27 05
Ch. A.-Verchère 6
Tel. 022 716 21 24
Route de Chancy 98
Tel. 022 709 00 35
Av. Blanc 51
Tel. 022 716 20 81
Av. Wendt 58
Tel. 022 716 21 16
Rue de Genève 144
Tel. 022 716 21 27
Unilabs Bern Pathologie
Tel. 031 387 30 30
Tel. 034 421 33 45
Tel. 058 864 52 40
Tel. 033 224 00 24
Via Rovere 8
Tel. 091 960 73 73
Route de la Corniche 3B
Phone +41 21 552 07 30
Fax +41 21 552 07 31